Elevate Capital Advisors LLC bought a new position in Danaher Co. (NYSE:DHR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,610 shares of the conglomerate's stock, valued at approximately $829,000.
Several other institutional investors have also made changes to their positions in the company. Heck Capital Advisors LLC acquired a new position in Danaher in the 4th quarter worth approximately $27,000. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at $31,000. Golden State Wealth Management LLC acquired a new stake in shares of Danaher in the fourth quarter worth $31,000. Strategic Financial Concepts LLC purchased a new position in shares of Danaher during the fourth quarter valued at $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in Danaher during the third quarter valued at $39,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Stock Performance
Shares of NYSE:DHR traded up $1.38 during trading on Thursday, reaching $203.56. The stock had a trading volume of 7,198,721 shares, compared to its average volume of 4,471,049. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a fifty day simple moving average of $230.49 and a two-hundred day simple moving average of $250.28. The firm has a market capitalization of $147.03 billion, a price-to-earnings ratio of 38.55, a P/E/G ratio of 2.68 and a beta of 0.83. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts' consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the business posted $2.09 earnings per share. As a group, analysts anticipate that Danaher Co. will post 7.67 earnings per share for the current fiscal year.
Danaher Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher's dividend payout ratio (DPR) is currently 20.45%.
Insiders Place Their Bets
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 11.10% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on DHR. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research note on Wednesday, October 23rd. KeyCorp boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an "overweight" rating in a research report on Wednesday, October 23rd. TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research report on Wednesday, October 23rd. Citigroup decreased their target price on shares of Danaher from $285.00 to $265.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, Barclays cut their price objective on Danaher from $275.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and a consensus price target of $278.00.
Check Out Our Latest Stock Report on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
